GLYC (GlycoMimetics) Earnings per share for the last four quarters

Public company logo of GlycoMimetics Inc. (GLYC)

The development of GlycoMimetics, Inc. (GLYC) is independent of economic cycles, relying exclusively on medical progress. However, the lack of profitability and uncertainty regarding test outcomes create high financial vulnerability. Business success is constrained by strict FDA regulations and laboratory research results. The current annual EPS TTM growth value demonstrates profit dynamics, where the latest mark is 38.80.

GLYC GlycoMimetics Earnings per share for the last twelve months (02/11/2024 - 02/20/2024)

GlycoMimetics Corp - analytical breakdowns and key metrics (GLYC)

- business market valuation indicators:
Fundamental valuation:GlycoMimetics Inc. (GLYC)
Signature product of GlycoMimetics Inc.

Analyzing the resilience of GlycoMimetics, Inc. (GLYC) requires evaluating profit dynamics through the lens of shareholder value. This indicator measures the percentage change in net income per share over a rolling year, revealing the efficiency of the business's capitalization. By examining the EPS growth rate over the last 12 months YoY, an investor determines the market consensus point between supply and demand. For a biopharmaceutical developer specializing in glycobiology, this metric reflects the commercial return on innovations in leukemia therapy.

Competitor analysis for GlycoMimetics, Inc.

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (immuneering.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months C4 Tx CCCC|Net earnings per share (EPS TTM) BDTX|Repare Therapeutics Inc. - Earnings per share for the last 12 months|PMV Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year KPTI|PPCB: Net earnings per share for the last 12 months|Cyclacel Pharmaceuticals - Earnings per share for the last four quarters|AADI: Net earnings per share (EPS TTM)|Aileron Therapeutics Inc - Earnings per share for the trailing year|BPMC (Blueprint Medicines Corp.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX